A share price of Astria Therapeutics Inc [ATXS] is currently trading at $4.76, down -3.84%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ATXS shares have gain 16.67% over the last week, with a monthly amount drifted -7.75%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Astria Therapeutics Inc [NASDAQ: ATXS] stock has seen the most recent analyst activity on April 29, 2025, when Cantor Fitzgerald initiated its Overweight rating and assigned the stock a price target of $47. Previously, JMP Securities started tracking the stock with Mkt Outperform rating on January 31, 2025, and set its price target to $26. On July 29, 2024, TD Cowen initiated with a Buy rating and assigned a price target of $35 on the stock. Evercore ISI started tracking the stock assigning a Outperform rating and suggested a price target of $18 on March 28, 2023.
Astria Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $3.56 and $12.92. Currently, Wall Street analysts expect the stock to reach $22.5 within the next 12 months. Astria Therapeutics Inc [NASDAQ: ATXS] shares were valued at $4.76 at the most recent close of the market. An investor can expect a potential return of 372.69% based on the average ATXS price forecast.
Analyzing the ATXS fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.35, Equity is -0.33 and Total Capital is -0.42. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.56 points at the first support level, and at 4.36 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.94, and for the 2nd resistance point, it is at 5.12.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Astria Therapeutics Inc [NASDAQ:ATXS] is 17.39. Also, the Quick Ratio is 17.39, while the Cash Ratio stands at 3.12.
